The company saw a 7% decline in biosimilar revenues in the second quarter of 2020 compared with the same quarter in 2019.
In the second quarter of 2020, net revenues climbed slightly for Biogen, of Cambridge, Massachusetts, although its biosimilar revenues declined somewhat amid the coronavirus disease 2019 (COVID-19)—challenged marketplace. Overall revenues climbed to $3.68 billion from $3.62 billion, according to the company's earnings statement.
Biosimilar revenues were $172 million, down 7% in the second quarter compared with the same period in 2019. The decline came despite efforts to extend commercialization agreements and earnings improvement reported for the first quarter of this year.
Earlier this week, the company announced the appointment of strategic finance and operations specialist Michael McDonnell as executive vice president and chief financial officer, effective August 15, 2020. McDonnell currently is executive vice president and chief financial officer at IQVIA, a data and technology leader in the health care field.
Biosimilar Revenue Breakdown
The etanercept biosimilar Benepali brought in $106 million in the second quarter compared with $120 million a year earlier, a 12% decline and off 20% from the first quarter of this year.
Biogen’s adalimumab product Imraldi notched sales of $45 million, down 5% from $47 million a year ago, and down 27% from the first quarter of 2020.
The company’s infliximab biosimilar (Flixabi) saw sales climb to $21 million from $17 million in the year earlier quarter, a gain of 23%. However, sales of this product were down 13% from the first quarter of the year.
Other Revenues
Biogen, which specializes in the neurosciences, saw some increases in its multiple sclerosis fumarate product revenue. Fumarate medication helps to improve iron deficiency—related anemia. Overall, multiple sclerosis product revenues dropped 2% quarter over quarter.
Revenues from dimethyl fumarate (Tecfidera) climbed to $1.18 billion from $1.15 billion a year ago; and sales of diroximel fumarate (Vumerity) were $9 million in the quarter just ended. The product was launched late last year at a controversial price of $88,000 for a year’s treatment.
In revenue guidance for the full year 2020, the company anticipated $13.8 billion to $14.2 billion versus its previous guidance of $14.0 billion to $14.3 billion.
Amid the COVID-19 pandemic, the company noted that supply channel inventory levels of its multiple sclerosis products increased by a value of $10 million during the second quarter, versus declines of $30 million in the second quarter of 2019 and $115 million in the first quarter of 2020.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Switching Patterns Highlight Nocebo Effect in European Patients Using Amgevita
July 23rd 2024About half of the patients in a European study who transitioned from reference adalimumab to a biosimilar version stayed on the biosimilar at the 1-year mark. However, researchers warned about a possible nocebo effect resulting in some patients switching back to the originator.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Eye on Pharma: EU Biosimilar Approval, Launches and Product Returns, Denosumab Switching Data
July 10th 2024The European Union approves a tocilizumab biosimilar and the US sees another launch, Genentech’s ophthalmology biobetter returns to the market, and Samsung Bioepis shares data on switching to its denosumab biosimilar.